Stockscreener 앱 받기
11.63
1.77%
-0.21
시장 영업 전:
11.54
-0.09
-0.77%
전일 마감가:
$11.84
열려 있는:
$11.73
하루 거래량:
1.34M
Relative Volume:
0.51
시가총액:
$1.61B
수익:
순이익/손실:
$-191.97M
주가수익비율:
-3.6833
EPS:
-3.1575
순현금흐름:
$-159.63M
1주 성능:
+8.19%
1개월 성능:
-15.42%
6개월 성능:
+27.10%
1년 성능:
+86.38%
1일 변동 폭
$0.00
$0.00
1주일 범위
$10.81
$12.12
52주 변동 폭
$4.88
$15.87
Compass Pathways Plc Adr Stock (CMPS) Company Profile
명칭
Compass Pathways Plc Adr
전화
1-716-676-6461
주소
3RD FLOOR, 1 ASHLEY ROAD, CHESIRE
Compare CMPS vs HCA, THC, EHC, DVA, FMS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPS
Compass Pathways Plc Adr
|
11.63 | 1.61B | 0 | -191.97M | -159.63M | -3.1575 |
HCA
Hca Healthcare Inc
|
467.31 | 101.17B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
270.63 | 21.79B | 21.46B | 2.65B | 3.35B | 19.23 |
EHC
Encompass Health Corp
|
126.01 | 12.43B | 6.07B | 793.80M | 464.40M | 5.9914 |
DVA
Davita Inc
|
186.10 | 11.87B | 13.84B | 1.10B | 1.49B | 10.42 |
FMS
Fresenius Medical Care Ag Adr
|
22.23 | 11.83B | 22.44B | 1.35B | 2.03B | 1.9002 |
Compass Pathways Plc Adr Stock (CMPS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-07-27 | 개시 | Wells Fargo | Equal Weight |
| 2026-07-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-05-22 | 개시 | Wolfe Research | Outperform |
| 2026-05-04 | 개시 | Jefferies | Buy |
| 2026-04-24 | 개시 | B. Riley Securities | Buy |
| 2025-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-02-27 | 개시 | Stifel | Buy |
| 2024-07-23 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-01 | 개시 | Morgan Stanley | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2022-11-21 | 재개 | Berenberg | Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-10-29 | 개시 | Oppenheimer | Outperform |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
| 2021-05-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-01 | 개시 | ROTH Capital | Buy |
| 2020-10-14 | 개시 | H.C. Wainwright | Buy |
| 2020-10-13 | 개시 | Berenberg | Buy |
| 2020-10-13 | 개시 | Canaccord Genuity | Buy |
| 2020-10-13 | 개시 | Cowen | Outperform |
| 2020-10-13 | 개시 | Evercore ISI | Outperform |
모두보기
Compass Pathways Plc Adr 주식(CMPS)의 최신 뉴스
CMPS: COMP360 shows durable efficacy in TRD, with launch and broad site readiness expected in the coming year - TradingView
CMPS: COMP360 targets TRD launch in H1 2027, leveraging strong data, payer support, and clinic readiness - tradingview.com
CMPS: Psychedelic therapy for TRD nears FDA approval, promising rapid, durable relief and broad adoption - tradingview.com
CMPS: COMP360's rapid, durable TRD results and robust launch prep signal a paradigm shift in psychiatry - tradingview.com
Fluence to develop psilocybin therapy training for Compass - investing.com
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training - Finviz
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51 - FXEmpire
Compass Pathways stock hits 52-week high at 15.4 USD - investing.com
Compass Pathways stock shows durable results in depression trial - investing.com
IRWD Stock Price, Quote & News - Syfe
Compass Pathfinder Limited: Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year - FinanzNachrichten.de
AQST Stock Price, Quote & News - Syfe
Lyell Immunopharma, Inc. (LYEL) Stock Price & News - Syfe
CytomX Therapeutics, Inc. (CTMX) Stock Price & News - Syfe
COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question - sahmcapital.com
Compass Pathways Target of Unusually High Options Trading (NASDAQ:CMPS) - MarketBeat
COMPASS (CMPS) Q2 2026 Earnings: EPS Falls Short of Its Estimate in the Reported Period; Share Move - dars.gov.et
COMPASS (CMPS) Q2 2026 Earnings: EPS Falls Short of Its Estimate in the Reported Period; Share Move - dars.gov.et
COMPASS (CMPS) Q2 2026 Earnings: EPS Falls Short of Its Estimate in the Reported Period; Share Move - dars.gov.et
How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions - Sahm
COMPASS (CMPS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Latest Reading; Session Move: Shares Close 0.79% HigherEarnings Acceleration Picks - dars.gov.et
COMPASS (CMPS) Earnings Snapshot: Profit Per Share Falls Below Its Benchmark in the Latest Reading - www.dars.gov.et
COMPASS (CMPS) Results Breakdown: The Available Earnings Metric Delivers a Miss for This Review; Closing Reaction: The Market Price Advances 1.31% for the Current SessionEarnings Call Transcript - careplusvn.com
COMPASS (CMPS) Results Breakdown: The Available Earnings Metric Delivers a Miss for This Review; Closing Reaction: The Market Price Advances 1.31% for the Current SessionAdjusted Earnings Analysis - dars.gov.et
COMPASS (CMPS) Results Breakdown: The Available Earnings Metric Delivers a Miss for This Review; Closing Reaction: The Market Price Advances 1.31% for the Current SessionMargin Compression Risk - dars.gov.et
COMPASS (CMPS) Technical Check: Climbs 1.31% to $13.90 for the Current Session; Level Position: the Near-Term Reference Band Stretches From $13.21 to $14.60 in the Current UpdateChart Pattern Alerts - careplusvn.com
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances - Yahoo Finance
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CMPS: COMP360 targets a 2027 launch, offering rapid, durable relief for TRD and advancing a PTSD program - TradingView
HC Wainwright Cuts Earnings Estimates for Compass Pathways - MarketBeat
COMPASS Pathways (CMPS) insider files Form 144 for 26,000 ADS sale - stocktitan.net
COMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run - Sahm
COMPASS Pathways plc (5Y6.F) stock price, news, quote and history - Yahoo Finance Singapore
Renaissance Technologies LLC Reduces Stock Position in Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
Compass Pathways partners with VA on psilocybin trial for veterans - Investing.com
Compass Pathfinder Limited: Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin - FinanzNachrichten.de
Compass Pathways (NASDAQ:CMPS) Trading 9.8% HigherWhat's Next? - MarketBeat
Earnings call transcript: COMPASS Pathways advances q2 2026 launch plans as stock slips - Investing.com
COMPASS Pathways Reports Q2 2026 Financials and Updates on COMP360 Clinical Programs - Kalkine Media
Why is Compass Pathways stock rallying today? By Investing.com - Investing.com South Africa
Compass Pathways Q2 Earnings Call Highlights - Yahoo Finance
CMPS: Q2 2026 net loss widened to $253.8M; Phase 3 TRD milestones achieved; cash runway into 2028 - TradingView
Seven Fleet Capital Management LP Buys 118,021 Shares of Compass Pathways PLC Sponsored ADR $CMPS - MarketBeat
CMPS Slips 1.9% as COMPASS Pathways Holds Above Key Support at $10.78Volume Breadth - careplusvn.com
200,000 Shares in Compass Pathways PLC Sponsored ADR $CMPS Acquired by Vivo Capital LLC - MarketBeat
CMPS Slips 1.9% as COMPASS Pathways Holds Above Key Support at $10.78High Reward Trades - www.dars.gov.et
CMPS Slips 1.9% as COMPASS Pathways Holds Above Key Support at $10.78Ratio Spread Trade - dars.gov.et
Compass Pathways earnings on deck ahead of pivotal FDA filing - Investing.com
COMPASS Pathways (CMPS) Holds Steady Near Resistance Amid Modest GainsATR Trailing Stop - dars.gov.et
COMPASS Pathways (CMPS) Slips 3.73% as Stock Nears Key Support at $10.31Continuation Pattern Picks - careplusvn.com
Compass Pathways Plc Adr (CMPS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Compass Pathways Plc Adr 주식 (CMPS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jenkins Annalisa | Former Director |
Aug 07 '26 |
Proposed Sale |
13.72 |
83,771 |
1,149,153 |
0 |
1.20%
0.77%
자본화:
|
볼륨(24시간):